Sight Sciences Reports Long-Term Efficacy of OMNI System

Sight Sciences has announced results from three newly published manuscripts analyzing both prospective and retrospective data on its OMNI Surgical System, further supporting the system’s role in minimally invasive glaucoma surgery (MIGS) and reinforcing the company's call for an interventional treatment mindset in glaucoma care.

The manuscripts include data from a 24-month prospective study, a large retrospective analysis of nearly 13,000 African American eyes, and a subgroup analysis of patients with primary open-angle glaucoma (POAG) who underwent standalone OMNI procedures.

24-Month Prospective Study: Durable IOP and Medication Reduction

One of the key studies included a 24-month prospective evaluation of 18 eyes treated with standalone OMNI following medication washout at baseline, 12 months, and 24 months. The findings demonstrated:

• A reduction in mean IOP from 26.1 mmHg to 16.4 mmHg at 12 months (–9.7 mmHg; p < .001) and to 15.5 mmHg at 24 months (–10.6 mmHg; p < .001)

• A decrease in mean number of medications from 1.8 to 0.9 at 12 months (p < .001) and to 0.5 at 24 months (p < .001)

• Two-thirds of patients were medication-free at 24 months

These results suggest durable pressure reduction and medication independence with a standalone OMNI procedure.

Retrospective Analysis

A retrospective observational study evaluated nearly 13,000 African American eyes, comparing outcomes across four cohorts:

• 12,057 eyes underwent cataract surgery alone

• 491 eyes received iStent inject

• 189 eyes received the Hydrus Microstent

• 91 eyes were treated with the OMNI Surgical System

The analysis showed that:

• Greater IOP reductions were seen in the MIGS + cataract surgery cohorts compared to cataract surgery alone

• The highest proportion of patients achieving ≥20% IOP reduction was observed in the OMNI cohort, followed by Hydrus and iStent inject

These findings underscore OMNI’s performance among patients at higher risk for glaucoma progression, particularly in underserved or late-diagnosed populations.

Long-Term Standalone Efficacy in Primary Open-Angle Glaucoma

A subgroup analysis of 220 eyes treated with standalone OMNI in patients with primary open-angle glaucoma demonstrated that:

• IOP reductions were sustained for up to 3 years,

• Efficacy was maintained regardless of lens status or disease severity

This further supports the OMNI Surgical System’s utility as a standalone intervention across a wide spectrum of glaucoma presentations.

Expert Commentary

Paul Badawi, Founder and CEO of Sight Sciences, commented: “These results demonstrate that when surgeons are given the right solutions, they are able to reduce a patient’s intraocular eye pressure (IOP) and reliance on medication and maintain those reductions over an extended period of time, 24 months or 36 months.”

Dr. Leon Herndon, Duke University Eye Center, added: “OMNI continues to deliver results for patients, whether it be patients undergoing cataract surgery, those that have already had cataract surgery and are now pseudophakic, or groups at historically higher risk for glaucoma, as demonstrated by our study.”

Dr. Herndon emphasized the importance of having tools like OMNI for mild to moderate glaucoma, especially for African American patients, who are often diagnosed at later stages of disease.

About the OMNI and OMNIEdge Surgical Systems

The OMNI Surgical System and OMNIEdge Surgical System are implant-free, minimally invasive technologies designed to reduce intraocular pressure in adult patients with primary open-angle glaucoma. Both systems offer a comprehensive MIGS approach by addressing multiple points of resistance within the conventional outflow pathway and are indicated in the United States for use as standalone procedures or in combination with cataract surgery.